NCT02719379View on ClinicalTrials.gov

Immune Response to Pneumococcal Polysaccharide Vaccine (23-valent) Predicts Asthma Status and Outcomes in Late Adolescents With Asthma

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

June 30, 2017

Study Completion Date

June 30, 2017

Conditions
Asthma
Interventions
BIOLOGICAL

Pneumonococcal Polysaccharide Vaccine 23-valent (PPSV-23)

Trial Locations (1)

55905

Mayo Clinic, Rochester

All Listed Sponsors
lead

Rohit Divekar

OTHER

NCT02719379 - Immune Response to Pneumococcal Polysaccharide Vaccine (23-valent) Predicts Asthma Status and Outcomes in Late Adolescents With Asthma | Biotech Hunter | Biotech Hunter